A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Esophageal Cancer
• Have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural requirements；
• The age of signing the informed consent is 18 -70 years, regardless of gender；
• Provide archived or fresh tumor tissue for vendor test;
• At least one measurable lesion according to RECIST v1.1 criteria；
• Subjects with pathology confirmed locally advanced unresectable or metastatic esophageal squamous cell carcinoma;
• The ECOG score is 0 or 1；
• Expected survival ≥12 weeks
• Good level of organ function
• Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.